Clinical trials
Non Small Cell Lung Cancer Metastatic clinical trials
Below are recruiting non small cell lung cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 765 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT06266299RecruitingPhase 1
Study of KK2269 for adults with solid tumors
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06272864Recruiting
A study looking at genetics of certain advanced cancers
This study tests the genes of your cancer to learn more about advanced breast, lung, melanoma, or sarcoma tumors. It may help doctors find better ways to treat these cancers in the future.
Rogers, ArkansasAges 18 years+ - NCT06276283RecruitingPhase 2
DZD9008 plus bevacizumab for EGFR-mutated advanced lung cancer
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06284317RecruitingPhase 3
Durvalumab after chemo and surgery for early lung cancer
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
Camperdown, New South WalesAges 18 years+ - NCT06295432RecruitingPhase 2
Study of two targeted drugs for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT06300177RecruitingPhase 3
New targeted pill vs. chemotherapy for KRAS G12C lung cancer
This trial compares a new targeted pill (D-1553) against a standard chemotherapy (docetaxel) for people with a specific type of advanced lung cancer (KRAS G12C mutation) whose cancer has stopped responding to first-line immunotherapy and chemotherapy.
Hefei, AnhuiAges 18 years+ - NCT06305715RecruitingPhase 2
Radiation before targeted therapy for advanced lung cancer
This trial tests if giving radiation to the main lung tumor before starting a targeted therapy pill can help delay the cancer from growing. It is for people with advanced non-small cell lung cancer that has a specific genetic change and who have not had targeted therapy before.
Milwaukee, WisconsinAges 18 years+ - NCT06305962RecruitingEarly Phase 1
Radioactive drug for advanced PD-L1 positive solid tumors
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
Kingswood, New South WalesAges 18 years+ - NCT06313541RecruitingPhase 2
Adaptive radiation with immunotherapy for advanced lung cancer
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
ShanghaiAges 18 years+ - NCT06315010RecruitingPhase 2
Repotrectinib for ROS1-positive lung cancer with brain spread
This clinical trial tests a new targeted therapy pill (repotrectinib) for people with ROS1-positive lung cancer that has spread to the brain. The pill is designed to enter the brain and attack cancer cells that other targeted treatments may not reach well.
GrazAges 18 years+ - NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05985330Recruiting
Study of FeNO as a marker for immunotherapy response in lung cancer
This trial is testing whether a simple breath test (FeNO) can predict how well immunotherapy works in people with advanced lung cancer who haven't had treatment before. It's for patients whose tumors have high PD-L1 levels and who will receive immunotherapy alone.
DijonAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New Haven, ConnecticutAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Little Rock, ArkansasAges 18 years+ - NCT07355205RecruitingPhase 1/Phase 2
Combination immunotherapy for advanced lung cancer
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
St Louis, MissouriAges 18 years+ - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Tucson, ArizonaAges 18 years+ - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06332755RecruitingPhase 1
Study of LB-LR1109 alone and with atezolizumab for cancer
This trial tests a new drug called LB-LR1109, alone or with atezolizumab, for adults with certain advanced solid tumors, including non-small cell lung cancer. It's for people whose cancer has worsened after standard treatments or who cannot have those treatments.
Fairfax, VirginiaAges 18 years+ - NCT06343064RecruitingPhase 1/Phase 2
Vebreltinib plus PLB1004 for EGFR-mutant lung cancer with MET changes
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
Birmingham, AlabamaAges 18 years+ - NCT06345729RecruitingPhase 3
Study of Calderasib and Pembrolizumab for Advanced Lung Cancer
This trial tests a new combination of two drugs (Calderasib and Pembrolizumab) in people with a specific type of advanced lung cancer (non-small cell lung cancer) that has a KRAS G12C mutation and high PD-L1 levels. It aims to see if this treatment can help shrink or control the cancer.
Bakersfield, CaliforniaAges 18 years+ - NCT06348927RecruitingPhase 2
Sunvozertinib plus anlotinib for first-line EGFR-mutant lung cancer
This trial tests a combination of two oral drugs (sunvozertinib and anlotinib) as a first treatment for advanced lung cancer with certain EGFR mutations plus other gene changes. It aims to see if this combination works better than standard treatments.
Changsha, HunanAges 18 years+
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non small cell lung cancer metastatic?
- Yes. Clin2 currently lists 765 recruiting non small cell lung cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non small cell lung cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non small cell lung cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.